# Bristol Myers Squibb (BMY) Financial Model

Free Excel 3-statement financial model and company analysis for Bristol Myers Squibb.

- Canonical: https://finamodel.com/companies/bristol-myers-squibb
- Industry: Pharmaceuticals
- Downloadable model: Yes
- Excel download: https://finamodel.com/company-models/BMY.xlsx

## Model Purpose

This model evaluates Bristol Myers Squibb's equity valuation and cash flow generation capacity, specifically testing whether the rapid ramp-up of its Growth Portfolio can successfully offset the steep revenue declines from the Revlimid patent cliff and impending Medicare price negotiations for Eliquis.

## Company Overview

Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company specialises in oncology, haematology, immunology, cardiovascular, and neuroscience therapeutic areas.

BMS operates as a single reportable segment but tracks its commercial performance across three distinct product groupings: the Growth Portfolio (newer launch products like Reblozyl, Breyanzi, Camzyos, and Cobenfy), Eliquis (a massive cardiovascular blockbuster), and the Legacy Portfolio (mature products facing loss of exclusivity, such as Revlimid, Pomalyst, and Sprycel). The United States is the primary market, contributing approximately 69% of total revenues, with international markets making up the remaining 31%. The business model is highly intellectual property-driven, relying on massive R&D investments and serial acquisitions (such as Celgene, MyoKardia, Karuna Therapeutics, and Mirati Therapeutics) to replenish its pipeline. BMS faces intense competitive pressure from other large pharma companies and generic/biosimilar manufacturers, alongside significant regulatory pricing headwinds from the US Inflation Reduction Act (IRA).

## Revenue Deep Dive



### Eliquis

- **Segment name:** Eliquis (reported separately or within In-Line Products)
- **Revenue driver formula:** Total Prescriptions (TRx) x Net Price per Script x BMS Profit Share Percentage
- **Historical growth rate:** 5% to 8% CAGR over the last 3 years
- **Key growth levers and headwinds:** Driven by volume growth in the oral anticoagulant market. The major headwind is the US Inflation Reduction Act (IRA), which mandates government-set "maximum fair prices" for Eliquis starting in 2026, alongside a 2025 agreement providing the drug free to Medicaid.
- **Pricing dynamics:** Highly rebated in the US commercial channel; facing severe statutory price cuts in Medicare Part D.
- **Revenue recognition notes:** Recognised upon delivery to wholesalers, net of estimated rebates, chargebacks, and discounts.
- **Seasonality:** Q1 is typically the weakest quarter due to the US Medicare Part D "donut hole" reset and higher patient out-of-pocket costs at the start of the year.

### Growth Portfolio (New Product Portfolio)

- **Segment name:** Growth Portfolio (includes Reblozyl, Breyanzi, Camzyos, Opdualag, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy)
- **Revenue driver formula:** Patient Starts x Compliance Rate x Net Price per Month
- **Historical growth rate:** 15% to 25% YoY (23% growth in Q4 2024)
- **Key growth levers and headwinds:** Driven by new indication approvals, geographic expansion, and physician adoption. Headwinds include manufacturing capacity constraints for cell therapies (Breyanzi, Abecma) and competitive launches.
- **Pricing dynamics:** Premium pricing for first-in-class or best-in-class therapies, particularly in rare diseases and oncology.
- **Revenue recognition notes:** Standard gross-to-net accounting; cell therapies are recognised when the final manufactured product is delivered to the treatment centre.
- **Seasonality:** Less seasonal than primary care drugs, though Q4 often sees a slight uptick due to year-end budget exhaustion in certain ex-US markets.

### Legacy Portfolio (Mature and LOE Products)

- **Segment name:** Legacy Portfolio (includes Revlimid, Pomalyst, Sprycel, Abraxane)
- **Revenue driver formula:** Prior Year Revenue x (1 - Generic Erosion Percentage)
- **Historical growth rate:** Negative 10% to 20% YoY decline
- **Key growth levers and headwinds:** Completely dominated by the headwind of generic entry. Revlimid is undergoing a volume-limited generic rollout that will eventually become unlimited, driving revenues toward zero.
- **Pricing dynamics:** Heavy discounting required to maintain any residual volume against generic competitors.
- **Revenue recognition notes:** High variability in gross-to-net adjustments as generic competition intensifies.
- **Seasonality:** Irregular, driven more by the exact timing of generic competitor launches than by calendar seasonality.

### Opdivo and Yervoy (Immuno-Oncology)

- **Segment name:** Opdivo / Yervoy (often grouped in In-Line or Growth depending on the reporting year)
- **Revenue driver formula:** Treated Patients x Duration of Therapy x Price per Infusion
- **Historical growth rate:** 4% to 8% YoY
- **Key growth levers and headwinds:** Growth driven by approvals in earlier lines of therapy (adjuvant/neoadjuvant settings) and subcutaneous formulations (Opdivo Qvantig). Headwinds include intense competition from Merck's Keytruda.
- **Pricing dynamics:** Relatively stable net pricing; competition is fought on clinical trial data and label expansions rather than price.
- **Revenue recognition notes:** Standard gross-to-net.
- **Seasonality:** Generally stable across the year.

## Cost Structure



### Variable Costs / COGS

- **Line-by-line breakdown:** Manufacturing costs, raw materials, royalty payments to alliance partners (e.g., Pfizer for Eliquis), profit-sharing expenses, and inventory step-up amortisation from acquisitions.
- **Gross margin range:** 71% to 76% on a non-GAAP basis over the last 5 years.
- **Key input costs and commodity exposures:** Active pharmaceutical ingredients (APIs), specialised manufacturing for biologics, and highly complex logistics for autologous cell therapies.
- **How COGS scales with revenue:** Generally linear, but margins compress as the product mix shifts from high-margin small molecules (Revlimid) to lower-margin partnered products (Eliquis) and high-cost-of-goods cell therapies.

### Operating Expenses

- **R&D:** Typically 20% to 22% of revenue (approximately $10 billion annually). Covers clinical trials, preclinical research, and regulatory filings. This line is highly sensitive to Acquired In-Process Research and Development (IPRD) charges, which can add billions in one-off expenses during acquisition years (e.g., 2024).
- **SG&A:** Typically 15% to 17% of revenue. Driven by commercial sales forces, marketing campaigns for new launches, and corporate overhead. BMS has an active strategic productivity initiative aiming to cut $2 billion in costs by 2027.
- **Depreciation & Amortisation:** High amortisation burden due to the Celgene and subsequent acquisitions. Amortisation of acquired intangible assets is usually excluded from non-GAAP metrics.
- **Stock-Based Compensation:** Moderate, typically 1% to 2% of revenue.
- **Restructuring / one-time charges:** Frequent, given the company's serial acquisition strategy and ongoing cost-cutting programmes.

### Margin Profile

- **Gross margin:** 71% to 76% (Non-GAAP).
- **Operating margin:** 35% to 40% (Non-GAAP), though GAAP margins are often much lower or negative in years with massive IPRD charges.
- **Net margin:** 25% to 30% (Non-GAAP).
- **Margin trend:** Compressing slightly due to the loss of high-margin Revlimid revenue, the increasing proportion of partnered/royalty-burdened revenue, and the high manufacturing costs of cell therapies.

## Balance Sheet Structure

- **Total assets:** Approximately $90 billion to $100 billion.
- **Key asset categories:** Intangible assets and goodwill make up the vast majority of assets, stemming from the $74 billion Celgene acquisition and recent multi-billion dollar buyouts of Karuna, Mirati, and RayzeBio.
- **Goodwill & intangibles as % of total assets:** Typically 50% to 60%.
- **Working capital profile:**
  - **Days Sales Outstanding (DSO):** 60 to 75 days (standard for pharma dealing with major wholesalers).
  - **Days Inventory Outstanding (DIO):** 80 to 100 days (biologics require long lead times).
  - **Days Payable Outstanding (DPO):** 50 to 65 days.
  - **Net working capital as % of revenue:** Positive, typically 5% to 10%.
  - **Is working capital positive or negative?** Positive. The company requires working capital to fund inventory and receivables.
- **PP&E:** Approximately $6 billion to $8 billion. Consists of global manufacturing facilities, particularly new investments in cell therapy and radiopharmaceutical plants.
- **Right-of-use assets / operating leases:** Material but not a dominant balance sheet item (approximately $1 billion).

## Capital Expenditure & Investment

- **Capex as % of revenue:** 2% to 3% (approximately $1.0 billion to $1.5 billion annually).
- **Maintenance capex vs. growth capex:** Roughly 40% maintenance, 60% growth (focused on expanding biologics, cell therapy, and radiopharmaceutical manufacturing capacity).
- **Major capex programmes underway or planned:** Expansion of cell therapy manufacturing sites in the US and Europe to alleviate supply bottlenecks for Breyanzi and Abecma.
- **Capitalised software / development costs:** Minimal relative to the scale of the business; R&D is expensed as incurred unless it results from an acquisition (IPRD).
- **M&A pattern:** Transformational and serial bolt-on acquirer. BMS relies on M&A to replenish its pipeline ahead of patent cliffs.
- **Typical acquisition multiple paid:** Highly variable, often based on peak sales multiples of pipeline assets rather than trailing EBITDA.

## Debt & Capital Structure

- **Total debt:** Approximately $35 billion to $40 billion.
- **Debt/EBITDA ratio:** 1.5x to 2.5x (Non-GAAP EBITDA).
- **Credit rating:** A2 (Moody's) / A (S&P).
- **Key debt instruments:** Senior unsecured notes (USD and EUR denominated).
- **Maturity profile:** Well-laddered, with average maturities extending beyond 10 years.
- **Interest rate profile:** Predominantly fixed-rate bonds.
- **Covenants:** Standard investment-grade covenants; no restrictive financial maintenance covenants.
- **Share repurchase programme:** Highly active. The company frequently uses excess free cash flow to buy back shares, often executing multi-billion dollar accelerated share repurchase (ASR) agreements.
- **Dividend policy:** Progressive dividend policy. Yield is typically 4% to 5%, with a payout ratio of roughly 35% to 45% of non-GAAP earnings.

## Cash Flow Characteristics

- **Operating cash flow conversion:** Very strong. OCF is typically $12 billion to $14 billion annually.
- **Free cash flow margin:** 20% to 25% of revenue.
- **Major non-cash items that bridge net income to OCF:** Amortisation of intangible assets, Acquired IPRD charges (which are often non-cash impairments or upfront equity/milestone issuances), and deferred income taxes.
- **Working capital cash flow impact:** Generally a slight use of cash as the Growth Portfolio expands, offset by declining receivables from the Legacy Portfolio.
- **Capex intensity:** Low (2% to 3% of revenue), making the business highly cash-generative.
- **Cash tax rate vs. GAAP effective tax rate:** The non-GAAP effective tax rate is typically 15% to 22%. GAAP tax rates can swing wildly (even turning negative) due to non-tax-deductible IPRD charges from acquisitions.

## Sheet Structure

1. **Control Panel:** Model toggles, scenario selectors (e.g., Base, Bull, Bear for IRA impact), and formatting macros.
2. **Assumptions:** Hardcoded inputs for macroeconomic drivers, tax rates, WACC, and share count.
3. **Revenue Build:** Detailed bottom-up forecast for Eliquis, Opdivo, Revlimid, Pomalyst, Sprycel, Yervoy, and the Growth Portfolio (broken out by key drugs like Reblozyl, Breyanzi, Camzyos, Cobenfy).
4. **Income Statement:** Consolidated GAAP and Non-GAAP P&L. Must explicitly show Acquired IPRD and Amortisation of Intangibles as separate line items to bridge GAAP to Non-GAAP EPS.
5. **Balance Sheet:** Standard assets, liabilities, and equity. Must include large line items for Goodwill and Intangible Assets.
6. **Cash Flow Statement:** Operating, Investing, and Financing cash flows.
7. **Debt Schedule:** Tranche-by-tranche bond maturity schedule, interest expense calculation, and mandatory debt paydown logic.
8. **Working Capital:** DSO, DIO, DPO schedules driving the balance sheet and cash flow statement.
9. **Depreciation & Amortisation:** PP&E waterfall and, crucially, the amortisation schedule for acquired intangible assets.
10. **DCF Valuation:** Free cash flow build, WACC calculation, terminal value, and implied share price.
11. **EPS Reconciliation:** A dedicated sheet bridging GAAP Net Income to Non-GAAP Net Income, adjusting for IPRD, amortisation, and restructuring costs.

## Key Financial Relationships

1. `Eliquis Revenue = Prior Year Eliquis Revenue * (1 + Volume Growth Rate) * (1 + Net Price Change)`
2. `Revlimid Revenue = Prior Year Revlimid Revenue * (1 - Generic Erosion Rate)`
3. `Growth Portfolio Revenue = Sum(Reblozyl, Breyanzi, Camzyos, Opdualag, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy)`
4. `Total Revenue = Eliquis Revenue + Opdivo Revenue + Legacy Portfolio Revenue + Growth Portfolio Revenue + Other Brands Revenue`
5. `COGS = Total Revenue * (1 - Gross Margin Percentage)`
6. `Non-GAAP R&D Expense = Total Revenue * Non-GAAP R&D Margin (excluding IPRD)`
7. `GAAP R&D Expense = Non-GAAP R&D Expense + Acquired IPRD Charges`
8. `Non-GAAP SG&A Expense = Total Revenue * SG&A Margin - Strategic Productivity Savings`
9. `Non-GAAP Operating Income = Total Revenue - COGS - Non-GAAP R&D - Non-GAAP SG&A`
10. `Interest Expense = Average Debt Balance * Weighted Average Interest Rate`
11. `Non-GAAP Net Income = (Non-GAAP Operating Income - Interest Expense + Other Income) * (1 - Non-GAAP Effective Tax Rate)`
12. `Free Cash Flow = Operating Cash Flow - Capital Expenditures`

## Cross-Sheet Dependencies

- The **Revenue Build** sheet is the foundation of the model. It feeds the top line of the **Income Statement**.
- The **Income Statement** generates Net Income, which flows to the top of the **Cash Flow Statement** and feeds Retained Earnings on the **Balance Sheet**.
- The **Working Capital** sheet uses revenue and COGS from the **Income Statement** to calculate receivables, payables, and inventory, which feed both the **Balance Sheet** and the **Cash Flow Statement**.
- The **Debt Schedule** uses Free Cash Flow from the **Cash Flow Statement** to determine discretionary debt paydown or share repurchases. The resulting debt balance feeds the **Balance Sheet** and calculates Interest Expense for the **Income Statement**.
- **Circularity Risk:** Interest expense depends on the debt balance, which depends on cash flow, which depends on net income, which depends on interest expense. A circularity breaker toggle must be included in the **Control Panel**.

## Sign Convention

- **Revenues and Assets:** Positive.
- **Expenses and Liabilities:** Positive on their specific schedules, but subtracted in aggregation formulas (e.g., `Gross Profit = Revenue - COGS`).
- **Cash Flow Statement:** Inflows are positive, outflows (including capex, dividends, and share repurchases) are negative.
- **Contra-accounts:** Accumulated depreciation and amortisation should be entered as negative numbers on the balance sheet.

## Things Most Likely to Go Wrong

- **Acquired IPRD Distortions:** BMS frequently records massive, one-time IPRD charges (e.g., $12 billion for Karuna in 2024). Failing to exclude these from Non-GAAP EPS and operating margin calculations will completely break the valuation.
- **IRA Price Cuts:** Eliquis faces Medicare negotiated prices in 2026. Models that extrapolate historical pricing trends without a structural step-down in 2026 will overvalue the company.
- **Revlimid Cliff:** The generic erosion curve is non-linear. Assuming a flat percentage decline will misrepresent the actual volume-limited generic settlement agreements.
- **GAAP vs Non-GAAP Tax Rates:** IPRD charges are often non-tax-deductible. Using the GAAP effective tax rate for cash flow forecasting will result in massive errors; the model must use the Non-GAAP tax rate (15% to 22%).
- **Amortisation Burden:** The Celgene acquisition created massive intangible assets. The amortisation of these assets depresses GAAP earnings but is a non-cash charge that must be added back for free cash flow calculations.
- **Cell Therapy Capacity:** Forecasting Breyanzi and Abecma based purely on demand will overestimate revenue; these products are frequently constrained by manufacturing capacity.
- **Foreign Exchange:** BMS has significant ex-US revenue. The model should ideally forecast on a constant-currency basis to avoid noise from FX translation.
- **Share Count Reduction:** BMS aggressively buys back stock. Failing to reduce the diluted share count over the forecast period will understate EPS.

## Validation Checks

- "Non-GAAP Gross margin should be in the 72% to 76% range; flag if outside this band."
- "Non-GAAP R&D as a percentage of revenue should remain between 20% and 23%."
- "Revlimid revenue must decline every year in the forecast period; flag if it shows growth."
- "Capex as a percentage of revenue should be between 2% and 3%."
- "Debt/EBITDA should remain below 3.0x to maintain the current credit rating."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Non-GAAP effective tax rate should be between 15% and 22%."
- "Free Cash Flow conversion (FCF / Non-GAAP Net Income) should be greater than 80%."

## Key Assumptions (Default Values)

| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Total Revenue Growth (Near-term) | -1.0 to 1.0 | % | 2025 guidance indicates relatively flat revenue as Growth Portfolio offsets Legacy declines |
| Eliquis Revenue Growth | 4.0 | % | Continued volume growth offset by higher US government channel rebates |
| Revlimid Generic Erosion Rate | -25.0 | % | Accelerating generic volume limits |
| Growth Portfolio Revenue Growth | 18.0 | % | Strong uptake of Cobenfy, Reblozyl, and Breyanzi |
| Non-GAAP Gross Margin | 73.0 | % | 2025 guidance and recent product mix shifts |
| Non-GAAP R&D Margin | 21.0 | % | Historical average, excluding one-time IPRD charges |
| Non-GAAP SG&A Margin | 15.5 | % | Reflects ongoing $2 billion strategic productivity initiative |
| Days Sales Outstanding (DSO) | 65 | Days | Historical average based on wholesaler terms |
| Days Inventory Outstanding (DIO) | 90 | Days | Requirement for complex biologic manufacturing |
| Days Payable Outstanding (DPO) | 55 | Days | Historical average |
| Capex % of Revenue | 2.5 | % | Historical average and ongoing facility expansions |
| Non-GAAP Effective Tax Rate | 17.0 | % | 2025 management guidance |
| Weighted Average Interest Rate | 4.5 | % | Blended rate of outstanding senior unsecured notes |
| Annual Share Repurchases | 3.0 | $ Billions | Estimated baseline based on historical capital allocation |
| Dividend Payout Ratio | 40.0 | % | Based on stated policy and recent dividend increases |
| WACC | 7.5 | % | Standard discount rate for large-cap diversified pharma |
| Terminal Growth Rate | -1.0 | % | Conservative assumption due to perpetual patent cliff cycles |

## Data Sources & Benchmarks

- **Filings:** SEC EDGAR (Form 10-K, 10-Q, 8-K), BMS Investor Relations website.
- **Key Peers:** Pfizer (PFE), Merck (MRK), AbbVie (ABBV), Johnson & Johnson (JNJ), Novartis (NVS).
- **Industry Data:** IQVIA for prescription volume data (TRx/NRx), Symphony Health for US market share.
- **Consensus Estimates:** Bloomberg, FactSet, or Visible Alpha for sell-side consensus on specific pipeline asset peak sales.
- **Regulatory Sources:** CMS.gov for Inflation Reduction Act (IRA) maximum fair price publications and Medicare Part D coverage data.

## Sources

- Bristol Myers Squibb 2024 and 2025 Earnings Releases (bms.com)
- Bristol Myers Squibb 2023 and 2024 Annual Reports on Form 10-K
- Investing.com BMY Financial Metrics and Earnings Transcripts
- TradingView BMY SEC 10-K Report Summaries
- StockTitan BMY Annual Report Summaries
- Fiscal.ai Gross Profit Margin Data for BMY

---

## Frequently asked questions

### What is Bristol Myers Squibb's primary business focus?

Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company specializes in therapeutic areas such as oncology, haematology, immunology, cardiovascular, and neuroscience.

### How does Bristol Myers Squibb generate its revenue, and what are its key product categories?

Bristol Myers Squibb generates revenue from its diverse portfolio of innovative medicines, tracked across three product groupings: the Growth Portfolio, Eliquis, and the Legacy Portfolio. The Growth Portfolio includes newer launch products like Reblozyl and Breyanzi, while Eliquis is a major cardiovascular blockbuster, and the Legacy Portfolio consists of mature products.

### What is the projected revenue growth rate for Bristol Myers Squibb in the financial model?

The financial model for Bristol Myers Squibb assumes a revenue growth rate of approximately 14.5%. This assumption is crucial for evaluating whether the rapid ramp-up of the Growth Portfolio can successfully offset revenue declines from patent cliffs.

### What is Bristol Myers Squibb's capital expenditure strategy, and what percentage of revenue is allocated to it?

Bristol Myers Squibb allocates approximately 2% to 3% of its revenue to capital expenditures annually, amounting to about $1.0 billion to $1.5 billion. Roughly 60% of this capex is for growth, focused on expanding biologics, cell therapy, and radiopharmaceutical manufacturing capacity.

### What is the main purpose of the Bristol Myers Squibb financial model, and what key challenges does it address?

The model's primary purpose is to evaluate Bristol Myers Squibb's equity valuation and cash flow generation capacity. It specifically tests whether the rapid ramp-up of its Growth Portfolio can successfully offset steep revenue declines from the Revlimid patent cliff and impending Medicare price negotiations for Eliquis.

### Can I download an Excel financial model for Bristol Myers Squibb, and what forecast horizon does it cover?

Yes, an Excel financial model for Bristol Myers Squibb is available for download. This model provides a forecast horizon covering fiscal years 2026 through 2030.

[Interactive forecast calculator](https://finamodel.com/companies/bristol-myers-squibb/forecast)